ARIA Widens Sales Turf, NRX Skips A Beat, NDRM Triples On Parkinson''s Study
The trial, dubbed KINSHIP, designed to enroll about 50 adult patients with mild to moderate atopic dermatitis is being conducted at clinical research centers in Canada. AQXP closed Tuesday's trading 6.46% higher at $ 7.25.
Read more on Nasdaq
Aquinox Pharma begins dosing in phase 2 trial of AQX-1125 in atopic dermatitis
The KINSHIP clinical trial is being conducted at clinical research centers in Canada as a randomized, double-blind, multicenter, placebo-controlled phase 2 trial evaluating the efficacy and safety of AQX-1125 in approximately 50 adult patients with …
Read more on pharmabiz.com
Moisturizer Reduces Eczema in High-Risk Newborns
The researchers conclude that applying a moisturizer from birth is "a feasible, safe, and effective approach" for the prevention of atopic dermatitis. If the benefit is confirmed in larger trials, this simple low-cost intervention could reduce the …
Read more on Medscape
Comments are closed.